Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC04.05.16
It probably won’t come as a surprise to many that the pharmaceutical industry has been increasingly embracing injectables as a consistently profitable business sector. It may be a surprise though, to find that seven of the top 10 pharmaceuticals by sales in 2014 were injectables (Table 1). This is a far cry from a decade earlier where only one product, Amgen’s Epogen, managed to crack the Top 10, sitting in the Number 9 position. Eight of these Top 10 products were oral products, and one, Advair, was an inhalation product. The sharp move towards injectables is the result of a number of important trends that are worth understanding.
It’s not just now, it’s also the future
The decade long shift in the top rank of pharmaceutical products is likely to be the new order for some time. While the existing portfolio of marketed pharmaceuticals is still heavily weighted to oral agents, the emerging pipeline reveals a significant change (Chart 1). Among pipeline programs injectables rank far ahead of oral programs, and pretty much equal all other programs as defined by delivery route. Looking a little clo
It’s not just now, it’s also the future
The decade long shift in the top rank of pharmaceutical products is likely to be the new order for some time. While the existing portfolio of marketed pharmaceuticals is still heavily weighted to oral agents, the emerging pipeline reveals a significant change (Chart 1). Among pipeline programs injectables rank far ahead of oral programs, and pretty much equal all other programs as defined by delivery route. Looking a little clo
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
